Abeona Therapeutics (NASDAQ:ABEO) Lowered to “Sell” Rating by StockNews.com

Abeona Therapeutics (NASDAQ:ABEO) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Tuesday.

Several other equities research analysts also recently commented on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $18.00 price target on shares of Abeona Therapeutics in a research report on Tuesday, October 29th. HC Wainwright reissued a “buy” rating and set a $15.00 price objective on shares of Abeona Therapeutics in a report on Thursday, October 31st.

Abeona Therapeutics Price Performance

Shares of NASDAQ:ABEO traded down $0.32 during trading hours on Tuesday, hitting $6.11. 922,542 shares of the company’s stock traded hands, compared to its average volume of 433,666. The company has a market cap of $264.41 million, a price-to-earnings ratio of -2.40 and a beta of 1.52. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.48 and a current ratio of 7.48. The company’s fifty day simple moving average is $6.15 and its two-hundred day simple moving average is $5.20. Abeona Therapeutics has a 52 week low of $3.05 and a 52 week high of $9.01.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings data on Monday, August 12th. The biopharmaceutical company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.42). As a group, equities analysts anticipate that Abeona Therapeutics will post -1.28 EPS for the current fiscal year.

Institutional Trading of Abeona Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of ABEO. Bank of New York Mellon Corp boosted its position in Abeona Therapeutics by 2.0% in the second quarter. Bank of New York Mellon Corp now owns 121,453 shares of the biopharmaceutical company’s stock worth $515,000 after purchasing an additional 2,434 shares during the last quarter. Acadian Asset Management LLC bought a new stake in Abeona Therapeutics in the first quarter valued at approximately $91,000. Charles Schwab Investment Management Inc. purchased a new position in Abeona Therapeutics during the 3rd quarter valued at about $151,000. GSA Capital Partners LLP lifted its position in shares of Abeona Therapeutics by 54.3% in the 3rd quarter. GSA Capital Partners LLP now owns 96,092 shares of the biopharmaceutical company’s stock worth $607,000 after purchasing an additional 33,831 shares during the period. Finally, Citigroup Inc. grew its stake in Abeona Therapeutics by 10.1% in the third quarter. Citigroup Inc. now owns 616,668 shares of the biopharmaceutical company’s stock worth $3,897,000 after purchasing an additional 56,332 shares during the period. 80.56% of the stock is currently owned by institutional investors and hedge funds.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.